Preoperative Total Serum Cholesterol As a Prognostic Factor for Survival in Patients with Resectable Non-small-cell Lung Cancer

Overview

Journal Wien Klin Wochenschr

Publisher Springer

Specialty General Medicine

Date 2009 Jun 30

PMID 19562293

Citations 17

Authors

Mihael Sok

Janez Ravnik

Maja Ravnik

Affiliations

Soon will be listed here.

Abstract

Background: Coexisting hypocholesterolemia in cancer has been known for a very long time but its relationship to cancer is still controversial. Hypocholesterolemia has been reported in patients with lung cancer, although its association with survival has not been explored.

Objectives: The purpose of the study was to determine whether preoperative total serum cholesterol is a prognostic factor for survival after lung cancer resection.

Methods: The retrospective study comprised 198 patients (162 men, 36 women) operated upon for resectable non-small-cell lung cancer (clinical stages I-IIIB) between January 1992 and April 1994. Total serum cholesterol concentration was determined preoperatively in each patient. The effects of sex, age, stage, histological type and preoperative total serum cholesterol concentration on survival were tested in univariate and multivariate analysis.

Results: Preoperative total serum cholesterol was a significant prognostic factor in both univariate and multivariate analysis. The median value for total serum cholesterol was 5.3 mmol/l and patients below that cut-off had significantly shorter overall survival times than patients in the high cholesterol group (5-year survival 41% vs. 56%, P < 0.05). In a multivariate Cox proportional-hazard regression model, only stage and preoperative total serum cholesterol were found to be of significance for survival (relative risk 0.84 for each mmol/l increase in concentration, CI 0.71-1.00, P < 0.05).

Conclusions: Our results suggest that preoperative total serum cholesterol may be an important prognostic factor for overall survival after lung cancer resection. It may prove to be a valuable tool in the follow-up of patients with lung cancer and in detection of high-risk cases.

Citing Articles

The Prognostic Value of Preoperative Total Cholesterol in Surgically Treated Oral Cavity Cancer.

Tsai Y, Tsai M, Kudva A, De Vito A, Lai C, Liao C Biomedicines. 2025; 12(12.

PMID: 39767804 PMC: 11726739. DOI: 10.3390/biomedicines12122898.

Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients.

Peng Q, Zhan C, Shen Y, Xu Y, Ren B, Feng Z BMC Cancer. 2024; 24(1):1549.

PMID: 39695484 PMC: 11657272. DOI: 10.1186/s12885-024-13265-8.

Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients.

Liang H, Liu D, Wang H, Ba Z, Xiao Y, Liu Y J Geriatr Cardiol. 2023; 20(10):737-747.

PMID: 37970226 PMC: 10630173. DOI: 10.26599/1671-5411.2023.10.002.

Untargeted Lipidomics of Non-Small Cell Lung Carcinoma Demonstrates Differentially Abundant Lipid Classes in Cancer vs. Non-Cancer Tissue.

Mitchell J, Flight R, Moseley H Metabolites. 2021; 11(11).

PMID: 34822397 PMC: 8622625. DOI: 10.3390/metabo11110740.

Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study.

Ma C, Wang X, Guo J, Liu P Lipids Health Dis. 2021; 20(1):69.

PMID: 34598703 PMC: 8487143. DOI: 10.1186/s12944-021-01492-y.

References

Strauss G . Prognostic markers in resectable non-small cell lung cancer. Hematol Oncol Clin North Am. 1997; 11(3):409-34. DOI: 10.1016/s0889-8588(05)70441-x. View

Rauchhaus M, Clark A, Doehner W, Davos C, Bolger A, Sharma R . The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003; 42(11):1933-40. DOI: 10.1016/j.jacc.2003.07.016. View

Flehinger B, Kimmel M, Melamed M . The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest. 1992; 101(4):1013-8. DOI: 10.1378/chest.101.4.1013. View

Lainscak M, Podbregar M, Anker S . How does cachexia influence survival in cancer, heart failure and other chronic diseases?. Curr Opin Support Palliat Care. 2008; 1(4):299-305. DOI: 10.1097/SPC.0b013e3282f31667. View

Hilbe W, Aigner K, Dittrich C, Eckmayr J, Fiegl M, Flicker M . [Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]. Wien Klin Wochenschr. 2007; 119(7-8):259-66. DOI: 10.1007/s00508-007-0792-5. View

Shiroeda O, Yamaguchi N, Kawai K . Stimulation of low density lipoprotein receptor activity by conditioned medium from a human cancer cell line. Cancer Res. 1987; 47(17):4630-3. View

Fearon K, Voss A, Hustead D . Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006; 83(6):1345-50. DOI: 10.1093/ajcn/83.6.1345. View

Tatidis L, Gruber A, Vitols S . Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J Lipid Res. 1998; 38(12):2436-45. View

Muldoon M, Marsland A, Flory J, Rabin B, Whiteside T, Manuck S . Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol. 1997; 84(2):145-9. DOI: 10.1006/clin.1997.4382. View

10.

Hughes D, Townsend P, Haslam P . Enhancement of the antigen-presenting function of monocytes by cholesterol: possible relevance to inflammatory mechanisms in extrinsic allergic alveolitis and atherosclerosis. Clin Exp Immunol. 1992; 87(2):279-86. PMC: 1554263. DOI: 10.1111/j.1365-2249.1992.tb02988.x. View

11.

Chyou P, Nomura A, STEMMERMANN G, Kato I . Prospective study of serum cholesterol and site-specific cancers. J Clin Epidemiol. 1992; 45(3):287-92. DOI: 10.1016/0895-4356(92)90089-6. View

12.

Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, MACHALSKI M . Serum total cholesterol and triglycerides levels in patients with lung cancer. Int J Mol Med. 2000; 5(2):201-5. DOI: 10.3892/ijmm.5.2.201. View

13.

Ettinger W, Miller L, Smith T, Parks J . Effect of interleukin-1 alpha on lipoprotein lipids in cynomolgus monkeys: comparison to tumor necrosis factor. Biochim Biophys Acta. 1992; 1128(2-3):186-92. DOI: 10.1016/0005-2760(92)90306-g. View

14.

Rauchhaus M, Coats A, Anker S . The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356(9233):930-3. DOI: 10.1016/S0140-6736(00)02690-8. View

15.

Schatzkin A, Hoover R, Taylor P, Ziegler R, Carter C, Larson D . Serum cholesterol and cancer in the NHANES I epidemiologic followup study. National Health and Nutrition Examination Survey. Lancet. 1987; 2(8554):298-301. DOI: 10.1016/s0140-6736(87)90890-7. View

16.

Kopple J . The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr. 2005; 81(6):1257-66. DOI: 10.1093/ajcn/81.6.1257. View

17.

Neaton J, Blackburn H, Jacobs D, Kuller L, Lee D, Sherwin R . Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992; 152(7):1490-500. View

18.

Eichholzer M, Stahelin H, Gutzwiller F, Ludin E, Bernasconi F . Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr. 2000; 71(2):569-74. DOI: 10.1093/ajcn/71.2.569. View

19.

Winawer S, Flehinger B, Buchalter J, Herbert E, Shike M . Declining serum cholesterol levels prior to diagnosis of colon cancer. A time-trend, case-control study. JAMA. 1990; 263(15):2083-5. View

20.

Fiorenza A, Branchi A, Sommariva D . Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res. 2001; 30(3):141-5. DOI: 10.1007/s005990070013. View